uniQure (NASDAQ:QURE) Announces Earnings Results, Misses Estimates By $0.53 EPS

uniQure (NASDAQ:QURE) posted its quarterly earnings data on Monday. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53), Zacks reports. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million.

uniQure Price Performance

Shares of QURE opened at $30.84 on Wednesday. The stock has a market capitalization of $1.69 billion, a PE ratio of -7.87 and a beta of 0.59. The company has a 50 day moving average price of $42.55 and a 200-day moving average price of $24.50. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. uniQure has a fifty-two week low of $5.50 and a fifty-two week high of $71.50.

Insider Buying and Selling

In other uniQure news, CFO Christian Klemt sold 15,000 shares of the stock in a transaction on Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the sale, the chief financial officer owned 217,730 shares of the company’s stock, valued at approximately $11,975,150. This trade represents a 6.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the completion of the transaction, the chief executive officer owned 651,454 shares in the company, valued at $27,009,282.84. This represents a 25.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 314,560 shares of company stock worth $12,362,568 in the last three months. Corporate insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Several hedge funds have recently modified their holdings of QURE. Tower Research Capital LLC TRC boosted its holdings in shares of uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 5,538 shares in the last quarter. Corient Private Wealth LLC lifted its position in uniQure by 100.0% during the second quarter. Corient Private Wealth LLC now owns 21,260 shares of the biotechnology company’s stock valued at $296,000 after acquiring an additional 10,630 shares during the last quarter. Militia Capital Partners LP acquired a new stake in uniQure in the second quarter valued at approximately $309,000. Engineers Gate Manager LP purchased a new position in uniQure in the second quarter worth $389,000. Finally, Legal & General Group Plc acquired a new position in shares of uniQure during the second quarter worth $497,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on QURE shares. Cantor Fitzgerald boosted their target price on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. Mizuho boosted their price objective on shares of uniQure from $30.00 to $60.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Wells Fargo & Company raised their target price on shares of uniQure from $65.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Leerink Partners decreased their price target on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday. Finally, Chardan Capital reissued a “buy” rating and issued a $53.00 price objective on shares of uniQure in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $66.08.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.